300 related articles for article (PubMed ID: 29709955)
1. Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.
Sato K; Niino M; Kawashima A; Yamada M; Miyazaki Y; Fukazawa T
Intern Med; 2018 Sep; 57(18):2647-2655. PubMed ID: 29709955
[TBL] [Abstract][Full Text] [Related]
2. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
Delgado S; Hernandez J; Tornes L; Rammohan K
BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
[TBL] [Abstract][Full Text] [Related]
4. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
[TBL] [Abstract][Full Text] [Related]
5. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
7. Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.
Bernard-Valnet R; Pignolet B; Biotti D; Ciron J; Lafontan JF; Dumas H; Bonneville F; Brassat D
Mult Scler Relat Disord; 2018 Oct; 25():216-218. PubMed ID: 30114625
[TBL] [Abstract][Full Text] [Related]
8. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
[TBL] [Abstract][Full Text] [Related]
9. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.
Vollmer B; Ontaneda D; Harris H; Nair K; Bermel RA; Corboy JR; Fox RJ; Vollmer T; Cohen JA; Alvarez E; Hersh CM
J Neurol Sci; 2019 Dec; 407():116498. PubMed ID: 31644992
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
[TBL] [Abstract][Full Text] [Related]
11. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
[TBL] [Abstract][Full Text] [Related]
12. No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study.
Zivadinov R; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Kolodny S; Silva D; Medin J; Weinstock-Guttman B;
Curr Med Res Opin; 2018 Aug; 34(8):1431-1440. PubMed ID: 29648900
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis.
Oommen VV; Tauhid S; Healy BC; Chua AS; Malik MT; Diaz-Cruz C; Dupuy SL; Weiner HL; Chitnis T; Bakshi R
J Neuroimaging; 2016; 26(2):184-7. PubMed ID: 26445919
[TBL] [Abstract][Full Text] [Related]
14. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
Sánchez P; Meca-Lallana V; Vivancos J
Mult Scler Relat Disord; 2018 Oct; 25():95-98. PubMed ID: 30056362
[TBL] [Abstract][Full Text] [Related]
15. Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.
Członkowska A; Smoliński Ł; Litwin T
Neurol Neurochir Pol; 2017; 51(2):156-162. PubMed ID: 28209440
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
[TBL] [Abstract][Full Text] [Related]
17. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.
Vollmer BL; Nair KV; Sillau S; Corboy JR; Vollmer T; Alvarez E
Ann Clin Transl Neurol; 2019 Feb; 6(2):252-262. PubMed ID: 30847358
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
19. Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.
Zivadinov R; Medin J; Khan N; Korn JR; Chitnis T; Naismith RT; Alvarez E; Dwyer MG; Bergsland N; Carl E; Silva D; Weinstock-Guttman B;
Mult Scler Relat Disord; 2019 Jan; 27():65-73. PubMed ID: 30342416
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.
Esposito F; Ferrè L; Clarelli F; Rocca MA; Sferruzza G; Storelli L; Radaelli M; Sangalli F; Moiola L; Colombo B; Martinelli Boneschi F; Comi G; Filippi M; Martinelli V
J Neurol; 2018 Apr; 265(4):896-905. PubMed ID: 29435643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
